分段式容积旋转调射技术应用于全脑放疗同步加量治疗多发性脑转移瘤
本研究回顾性分析10例多发性脑转移瘤患者(40-120个转移灶,中位76个),比较螺旋断层放疗、分段式容积旋转调射(P-VMAT)和常规双弧容积旋转调射(DA-VMAT)的剂量学参数。P-VMAT在全脑靶区和转移灶覆盖上与螺旋断层放疗无显著差异,适形性更好,全脑V44显著降低,危及器官最大剂量下降;DA-VMAT因全脑V44过高(54.7±8.2%)临床不可接受。
要点
- P-VMAT与螺旋断层放疗在全脑靶区和转移灶平均覆盖上无显著差异(p>0.05)。
- P-VMAT较螺旋断层放疗改善全脑靶区适形性(p<0.05),全脑V44从38.2±12.9%降至23.3±9.4%(p<0.05)。
- DA-VMAT因全脑V44过高(54.7±8.2%)临床不可接受。
核心结论
- P-VMAT适用于全脑放疗同步加量治疗多发性脑转移瘤,与螺旋断层放疗相比覆盖相当、适形性更好、V44更低且危及器官剂量保护更优。
- DA-VMAT即使对于相对较多脑转移灶且计划复杂度高的情况也未通过临床实践要求。
- 患者特异性验证表明P-VMAT临床应用的可行性。
研究设计与样本
- 回顾性分析10例多发性脑转移瘤患者(40-120个转移灶,中位76个),均接受螺旋断层放疗的全脑放疗同步加量。
- 处方剂量为全脑放疗40 Gy/20次、同步加量60 Gy/20次。
- 设计分段式容积旋转调射计划(7个弧,每个弧准直器旋转45°,野宽限制2.5 cm,相邻弧重叠0.5 cm),并与螺旋断层放疗和常规双弧容积旋转调射计划进行剂量学比较。
- 采用ArcCHECK模体测量验证P-VMAT计划。
主要发现
- 螺旋断层放疗与P-VMAT在全脑靶区和转移灶平均覆盖上无显著差异(p>0.05)。
- P-VMAT较螺旋断层放疗改善全脑靶区适形指数(p<0.05)。
- 全脑V44(全脑放疗处方剂量的110%,即44 Gy)接受体积从螺旋断层放疗的38.2±12.9%降至P-VMAT的23.3±9.4%(p<0.05)。
- 海马、视神经、视交叉和脊髓等危及器官最大剂量在P-VMAT下下降(p<0.05)。
- DA-VMAT的全脑V44为54.7±8.2%,因过高而临床不可接受。
关键数值与推荐
- 全脑放疗处方剂量40 Gy/20次,同步加量处方剂量60 Gy/20次。
- 全脑V44定义为全脑放疗处方剂量的110%(44 Gy)所对应的接受体积。
- P-VMAT计划采用7个弧,每个弧准直器旋转45°,野宽限制2.5 cm,相邻弧重叠0.5 cm。
- 伽马通过率分析采用3%/3 mm标准和10%阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study implemented a piecewise volumetric modulated arc therapy (P-VMAT) for realizing whole-brain radiation therapy (WBRT) with simultaneous integrated boost (SIB) for multiple brain metastases (> 40 metastases) with a conventional C-arm linear accelerator. MATERIALS AND METHODS: This study retrospectively analyzed 10 patients with multiple brain metastases (40-120 metastases, median 76), who underwent WBRT and SIB using helical tomotherapy (HT). The prescribed doses were 40 Gy/20 f and 60 Gy/20 f for WBRT and SIB, respectively. Corresponding new HT plans were designed with P-VMAT using 7 arcs. For each arc, the collimator was rotated to 45°, and the field width was limited to 2.5 cm with 0.5 cm overlap with adjacent arcs. Thus, each arc covered only one section of the brain target volume. A conventional dual arc VMAT (DA-VMAT) plan was also designed. HT, P-VMAT, and DA-VMAT plans were compared using dose distribution reviews and dosimetric parameters. ArcCHECK phantom measurements were performed for verification of P-VMAT plans. RESULTS: No significant differences in the mean coverage of the whole-brain target and metastases were observed between HT and P-VMAT (p > 0.05). The conformity index for the whole-brain target improved with P-VMAT compared with HT (p < 0.05). Furthermore, the volume of 44 Gy V44 (110% of prescribed dose for WBRT) received for whole-brain significantly reduced with P-VMAT from 38.2 ± 12.9% to 23.3 ± 9.4% (p < 0.05), and the maximum dose for organs at risks such as the hippocampus, optical nerve, optical chiasm, and spinal cord declined with P-VMAT (p < 0.05). Unlike HT and P-VMAT, DA-VMAT was clinically unacceptable because V44 in the whole-brain was too high (54.7 ± 8.2%). The mean absolute dose gamma passing rate for P-VMAT plans was 97.6 ± 1.1% (3%/3 mm criterion, 10%). CONCLUSIONS: P-VMAT is favorable for WBRT and SIB for multiple brain metastases. It provides comparable coverage of whole-brain target and SIB, with better conformity, lower V44, and better dose sparing of organs at risk compared with HT. Furthermore, results show that DA-VMAT fails clinical practice even for a relatively large number of brain metastases with a high degree of plan complexity. The patient specific verification demonstrates the feasibility of P-VMAT for clinical application.
引用
- Xu Y, Xu Y, Men K, et al. Application of piecewise VMAT technique to whole-brain radiotherapy with simultaneous integrated boost for multiple metastases. Radiat Oncol. 2022. PMID: 35526019. doi:10.1186/s13014-022-02059-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。